Z
Zahra Younoszai
Researcher at Inova Health System
Publications - 30
Citations - 1793
Zahra Younoszai is an academic researcher from Inova Health System. The author has contributed to research in topics: Fatty liver & Steatohepatitis. The author has an hindex of 15, co-authored 30 publications receiving 1526 citations. Previous affiliations of Zahra Younoszai include Inova Fairfax Hospital.
Papers
More filters
Journal ArticleDOI
Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality
Zobair M. Younossi,Zobair M. Younossi,Maria Stepanova,Maria Stepanova,Nila Rafiq,Hala R. Makhlouf,Zahra Younoszai,Ritambhara Agrawal,Zachary Goodman +8 more
TL;DR: A diagnosis of NASH by the original criteria for NAFLD subtypes and the current study's criteria for NASH were in almost perfect agreement, but their level of agreement with the NAS and Brunt criteria was lower.
Journal ArticleDOI
Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD).
Maria Stepanova,Maria Stepanova,Nila Rafiq,Hala R. Makhlouf,Ritambhara Agrawal,Ishmeet Kaur,Zahra Younoszai,Arthur J. McCullough,Zachary Goodman,Zachary Goodman,Zobair M. Younossi,Zobair M. Younossi +11 more
TL;DR: This long-term follow-up of NAFLD patients confirms that NASH patients have higher risk of liver-related mortality than non-NASH patients and type II diabetes are at highest risk for overall and liver- related mortality.
Journal ArticleDOI
A Biomarker Panel for Non-alcoholic Steatohepatitis (NASH) and NASH-Related Fibrosis
Zobair M. Younossi,Zobair M. Younossi,Zobair M. Younossi,Sandra Page,Sandra Page,Nila Rafiq,Nila Rafiq,Aybike Birerdinc,Aybike Birerdinc,Maria Stepanova,Maria Stepanova,Noreen Hossain,Arian Afendy,Arian Afendy,Zahra Younoszai,Zahra Younoszai,Zachary Goodman,Ancha Baranova,Ancha Baranova,Ancha Baranova +19 more
TL;DR: ThisNAFLD Diagnostic Panel based on a clinical and laboratory data has good performance characteristics and is easy to use and could become useful in the management of patients with NAFLD.
Journal ArticleDOI
Predictors of health-related quality of life in patients with chronic liver disease.
Arian Afendy,J. B. Kallman,Maria Stepanova,Maria Stepanova,Zahra Younoszai,R. D. Aquino,Giampaolo Bianchi,Giulio Marchesini,Zobair M. Younossi,Zobair M. Younossi +9 more
TL;DR: This data indicates that liver disease patients with chronic liver diseases are more likely to have poorer quality of life than other patients to have had a positive experience with smoking.
Journal ArticleDOI
The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment:
TL;DR: This review will summarize the data regarding these interferon-free regimens, including Gilead's Harvoni (sofosbuvir/ledipasvir), AbbVie's Viekira Pak (paritaprevir/ritonavir/ombitasvir with dasabuvir), and Janssen’s Olysio (simeprevir) with sofOSbuvir.